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Abstract 
The development of a RP-HPLC method for Montelukast in the presence of its impurity and 
degradation product generated from force degradation studies drug was exposed through various degradation 
stress conditions and found to be stable column used BDS Hypersil C18 (250 mm x 4.6mm) 5um. Mobile 
phase was used in mixture of Buffer and Acetonitrile (30:70, v/v). The HPLC method was developed and 
validated with respect to linearity, precession, accuracy, ruggedness and specificity.  
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1. Introduction 
Montelukast sodium1-3 [Fig.1] is 
Antiasthmatic, Antiallergic, Antinflammatory and 
Cryoprotective Agent. Montelukast sodium is a 
selective and orally active Leucotriene   receptor 
antagonist that inhibits the cysteinyl CysLT1 receptor 
which is used in respiratory disorder as  leukotrine 
antagonist. Chemically it is Sodium Salt of 1-[[[(1R)-
1[3-[(1E)-2-(7-chloro-2-quinolinyl)  ethenyl]phenyl]- 
3-[2-(1-hydroxy-1- methyl ethyl)phenyl)  propyl] 
thio]methyl]cyclopropane acetic acid. Montelukast 
sodium is a white to pale yellow hygroscopic powder 
and Well absorbed orally excreted by biliary only 1% 
in urine. Montelukast sodium is soluble in water and 
methanol; practically insoluble in Acetonitrile. 
Adverse effects of Montelukast sodium are Stomach 
pain, headache, nausea, dizzziness, flu, cough, fever, 
stuffy nose. Impurities of Montelukast sodium are 
Sulfoxide impurity [Fig.2], Hydroxy   compound 
[Fig.3], Dihydro impurity [Fig.4], Styrene impurity 
[Fig.5]. Chemically, Sulfoxide impurity is 1-[[[(1R)-
1[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl] phenyl]- 
3-[2-(1-hydroxy-methylethyl)phenyl)propyl]  
sulfinyl]methyl)cyclopropane  acetic acid, Hydroxyl 
impurity is [(E)]-2-[3[(S)-[3-[2-(7-chloro-2-
quinolinyl)-ethenyl] phenyl]-3-hydroxypropyl] 
phenyl]-2-propanol, Dihydro impurity is 1-[[[(1R)-
1[3-[2-(7-chloro-2-quinolinyl)ethenyl]  phenyl] - 3-
[2-(1-hydroxy-1-methylethyl)phenyl) 
propyl]thio]methyl] cyclopropane  acetic acid and 
Styrene impurity is 1-[[[(1R)-1[3-[(1E)-2-(7-chloro-2 
quinolinyl) ethenyl] phenyl]-3-[2-(1-(1methyl) 
etenyl)phenyl) propel] thio] methyl] cyclopropane  
acetic acid.                          
Literature survey6-8  was carried out that no 
method has been reported for Development of 
Analytical Method and Validation for determination 
of Related Substances of Montelukast from 
Montelukast Sodium Chewable tablets.  The present 
work is undertaken with an Objective to develop a 
new in-House, economical, simple, accurate, precise 
and reproducible Method for determination of Related 
Substances of Montelukast from Montelukast Sodium 
Chewable tablets by RP-HPLC method4-5 and its 
validation (a non Pharmacopoeial, non compendial 
method).
 
                                                     
Fig 1 : Structure of Montelukast Sodium                            Fig 2 : Structure of Sulfoxide impurity                                                                                                           
                                 
Fig 3 : Structure of Hydroxide impurity                          Fig 4 : Structure of Dihydroxide impurity 
 
Fig 5: Structure of Styrene impurity 
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2. Methods and Materials 
 
2.1 Chemicals and Reagents:  
All the solvents and chemicals used were of 
HPLC and analytical grade. Mili Q water and 0.45 
µm Teflon filter was used throughout the 
experimental work. The gift drug samples of 
Montelukast Sodium were provided by Ajanta 
Pharmaceuticals, Kandivli, Mumbai. Chemicals and 
Reagents Used are Triethylamine (AR grade), Ortho 
Phosphoric Acid (AR grade), Sodium Dihydrogen 
orthophosphate dihydrate (AR grade), Acetonitrile, 
Water, Methanol.                               
2.2 Instrument:  
The chromatographic separation performed 
using Jasco  HPLC System with PDA detector, model 
2080.31. Software used to monitor was Borwin and 
Quaternary pump is applied. Analytical balance is 
used, Make Sartorious (Model AB - 20.04). pH meter  
was also used, Labindia Make, Model pH System 
362. 
2.3 Preparation of Mobile Phase:  
Buffer and  Acetonitrile (30:70 v/v) mixed  
properly 300 mL of Buffer and 700 mL of 
Acetonitrile and sonicated for 5 minutes to degased. 
2.3.1 Buffer Preparation:  
Dissolved 3.9 gm of Sodium dihydrogen 
orthophosphate dihydrate in 1000 ml of HPLC water, 
1.0 ml of triethylamine was added  and  pH was 
adjusted to 4.6 with diluted orthophosphoric acid. 
Solution was filtered  through 0.45µ nylon membrane 
filter. 
2.3.2 Preparation of diluent:  
Methanol of HPLC grade was selected as 
common solvent for preparation of stock solution and 
developing spectral characteristics of drugs, further 
dilutions from stock solutions were made in the 
mixture of Water and Acetonitrile in the ratio 10:90. 
2.3.3 Blank Preparation:  
Use diluent as a blank. 
2.4 Selection of Analytical Wavelength:  
MONTE WS (20.8 mg) was weighed and 
transfered into 100 mL volumetric flask. Then 50 mL 
of diluents were added, sonicated to dissolve and 
diluted  up to the mark with diluent and mixed (200 
ppm of MONTE) and further diluted ( 1 ml of 
Preparation to 200 ml with diluent). The solutions 
were scanned in the range of 200-400 nm. The spectra 
was shown in the Fig.6 
2.5 Sulphoxide impurity stock preparation 
(Solution A):  
Weighed and transfered about 1 mg of 
Sulphoxide impurity standard into 10 mL volumetric 
flask. 5mL of diluent were added, sonicated to 
dissolve and diluted up to the mark with diluent and 
mixed (100 ppm of Sulphoxide impurity). 
2.6 Hydroxy impurity stock preparation (Solution 
B): 
Weighed and transferred about 1 mg of 
Hydroxy impurity standard into 10 mL volumetric 
flask. 5mL of diluent were added, sonicated to 
dissolve and diluted up to the mark with diluent and 
mixed (100 ppm of Hydroxy impurity). 
2.7 Dihydro impurity stock preparation (Solution 
C): 
Weighed and transferred about 1 mg of 
Dihydro impurity standard into 10 mL volumetric 
flask. 5mL of diluent were added, sonicated to 
dissolve and diluted up to the mark with diluent and 
mixed (100 ppm of Dihydro impurity). 
2.8 Styrene impurity stock preparation (Solution 
D): 
Weighed and transferred about 1 mg of 
Styrene impurity standard into 10 mL volumetric 
flask. 5mL of diluent were added, sonicated to 
dissolve and diluted up to the mark with diluent and 
mixed (100 ppm of Styrene impurity). 
2.9 Montelukast Sodium standard stock 
preparation: 
Montelukast Sodium (20.8 mg) was weighed 
and transfed into 100 mL volumetric flask. Then 50 
mL of diluents were added, sonicated to dissolve and 
diluted up to the mark with diluent and (200 ppm of 
MONTE).  
2.10 Standard Preparation:  
1 mL of Montelukast Sodium standard stock 
solution preparation were diluted to 200 mL with 
diluent. 
2.10.1 Resolution preparation:  
Solution A, solution B, solution C and 
solution D( 0.2 mL of each) were  pipette out and 0.1 
mL Montelukast Sodium standard stock preparation 
was added in 20 mL volumetric flask and diluted up 
to the mark with diluent (1 ppm each). The 
chromatogram was shown in the Fig.7 
2.10.2 Sample preparation:  
Transfed 10 intact 5 mg Chewable tablets 
into 250 mL volumetric flask.and added 125 mL of 
diluent and sonicated for 15 minutes with intermittent 
shaking.  Maintain the water of sonicator at room 
temperature within sonication. Futher diluted upto the 
mark with diluent and filtered through 0.45µ 
membrane filter (200 ppm). 
2.11 Optimization of Chromatographic Condition 
for Estimation of Drugs:  
The mobile phase was allowed to equilibrate 
with stationary phase until steady baseline was 
obtained. The standard solution containing 
Montelukast Sodium was run and different individual 
solvents as well as combinations of solvents have 
been tried to get a good separation and stable peak. 
Each mobile phase was filtered through 0.45 µm 
Teflon filter. 
   Finally, the optimal composition of the 
mobile phase, Buffer & Acetonitrile (30:70, v/v ) was 
selected. It gave high resolution of Montelukast 
Sodium with minimal tailing.  
2.12 System Suitability Test:  
System suitability is a pharmacopoeial 
requirement and is used to verify, whether the 
resolution and reproducibility of the chromatographic 
system are adequate for analysis to be done. The tests 
were performed by collecting data from five replicate 
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injections of standard solutions. Resolution solution 
was injected and resolutions of the major adjacent 
peaks were checked. Standard preparation was injected 
in six replicates and % RSD for area of peak due to 
Montelukast was calculated. 
2.13 Validation Parameters9-10  
i)  Specificity:  
Specificity of an analytical method is its 
ability to measure accurately and specifically the 
analyte of interest without interferences from blank, 
placebo and impurities. 
Specificity by spiking impurities: 
Placebo preparation:  
Transfered 10 placebo tablets in 250 mL 
volumetric flask and proceed further as per the test 
preparation. 
Impurity Preparation:  
Dilute 1 mL of solution A, solution B, 
solution C, & solution D to separate 100 mL 
volumetric flask with diluent to produce 1 ppm of 
Sulphoxide impurity, Hydroxy impurity, Dihydro 
impurity, & Styrene impurity respectively. 
Test preparation:  
As per test preparation for 5 mg Chewable 
tablets described in the above preparation. 
Spiked Test preparation:  
Transfered 10 intact tablets into 250 mL 
volumetric flask. Added 125 mL of diluent and 
sonicated for 15 minutes with intermittent shaking. 
Maintained the water of sonicator at room 
temperature within sonication.  Added 2.5 mL of each 
Solution A1, Solution B1, Solution C1 and Solution 
D1 and dilute upto the mark with diluent and filter 
through 0.45µ membrane filter. 
       Injected  Blank preparation, Resolution 
preparation, Standard preparation in six replicates, 
Placebo preparation, Test preparation, Sulphoxide 
impurity preparation, Hydroxy impurity preparation, 
Dihydro impurity preparation, Styrene impurity 
preparation, Test spiked preparation and recorded the 
chromatograms. Calculated % RSD of the area of 
Montelukast from Standard preparation. 
Limit of Quantitation (LOQ):  
The quantitation limit of an individual 
analytical procedure is the lowest amount of analyte 
in a Test that can be quantitatively determined with 
suitable precision, accuracy respectively.  
 The limit for quantitation is established by standard 
deviation of response and the slope or by the signal to 
noise ratio whichever is appropriate.  
a) LOQ by Linearity:    
LOQ was Calculated by standard deviation of 
response and the slope from 0.2 ppm to 2.0 ppm of 
linearity. Prepare LOQ solution by subsequent 
dilution of respective impurity and Montelukast 
sodium working standard solutions. LOQ solution 
prepared by weighed and transferred accurately 0.920 
mg of Sulphoxide impurity standard, 0.990 mg of 
Hydroxy impurity standard, 1.223 mg of Dihydro 
impurity standard, 1.229 mg of Styrene impurity 
standard in separate 20 mL volumetric flask and 20.8 
mg of Montelukast Sodium working standard added 
in 100mL Volumetric flask. Diluents was added to the 
flask and sonicated for 5 minutes. Pipetted out 0.026 
mL of Sulphoxide Impurity, 0.026 mL of Hydroxy 
impurity, 0.026 mL of Dihydro impurity, 0.150 mL of 
Styrene impurity, 0.024 mL of Montelukast Sodium, 
in 100 mL volumetric and diluted upto the mark with 
diluent. Inject six replicates of LOQ solution. 
Calculate % RSD for peak area. Incorporate this LOQ 
area for linearity. 
                                    10 X Std. Deviation 
LOQ     =   ------------------------------ 
                                       Slope 
b) LOQ by Signal to noise ratio:  
LOQ solution (Concentration higher than 
LOD) was prepared by subsequent dilution of 
respective impurity and MONTE WS solution. Six 
replicates of LOQ were injected S/N ratio was 
determined from baseline noise. %RSD were 
calculated for peak area and these LOQ area was 
incorporated for linearity  
ii) Limit of Detection (LOD): 
The detection limit is the lowest amount of 
analyte in a Test that can be detected, but not 
necessarily quantified, under the stated experimental 
conditions. The limit for detection was established by 
standard deviation of response and the slope or by the 
signal to noise ratio whichever is appropriate.  
a) LOD by Linearity:  
LOD was Calculated by standard deviation 
of response and the slope from 0.2 ppm to 2.0 ppm of 
linearity. Prepare LOD solution (as per LOQ solution) 
by subsequent dilution of respective impurity and 
Montelukast Sodium working standard solutions. 
Inject three replicate injections of this solution. The 
limit for detection was established by signal to noise 
ratio. 
      3.3 X Std. Deviation 
LOD     =   ------------------------------ 
                                 Slope 
b) LOD by signal to noise ratio:  
Prepare LOD solution by subsequent dilution 
of respective impurity and Montelukast Sodium 
working standard solutions. Inject three replicate 
injections of this solution. 
iii) Linearity and Range: 
Linearity:  
The ability of a method to produce results 
those are directly proportional to the concentration of 
the analyte in Tests within a given range. Linearity 
was performed at 8 levels, viz. LOQ, 20%, 50%, 
75%, 100%, 125%, 150% and 200% w.r.t. 
Specification concentration of known impurity (1 
ppm of each impurity) and LOQ, 50%, 125%, 188%, 
250%, 313%, 375% and 500% w.r.t. Specification 
concentration of unknown impurity (0.4 ppm of 
Montelukast). Response factor is calculated by 
plotting the graph of Area vs. Concentration for 0.50 
ppm to 2.00 ppm of linearity solution and by using 
following formula.  
                              Slope of Montelukast Standard 
Response Factor =   ----------------------------------------------- 
                                              Slope of Impurity 
Research Article                                                                                         Charde et al /2014 
 
65 
 
Range:  
The range of analytical procedure is the 
interval between the upper & lower concentration of 
analyte in the Test for which it has been demonstrated 
that the analytical procedure has a suitable level of 
precision, accuracy & linearity. The range is derived 
from the linearity studies. 
iv) Accuracy : 
The accuracy of an analytical procedure 
expresses the closeness of agreement between the 
value, which is accepted either as a conventional true 
value or an accepted reference value and the value 
found. Accuracy may often be expressed as percent 
recovery by assay of known, added amounts of 
analyte. Accuracy is a measure of the exactness of the 
analytical method that is true for all practical purpose. 
A. Accuracy (Recovery) for Known impurities: 
 Performed accuracy at 4 levels, viz. LOQ, 
50%, 100% and 200% of specification concentration. 
All the known impurities were spiked in the Test and 
compare with the respective impurity standard. 
Calculated % recovery of each impurity by 
subtracting the area of known impurities present in 
the unspiked Test. 
Impurity standard preparation:  
 Weighed and transferred about 5 mg of 
each Sulphoxide impurity, Hydroxy impurity, 
Dihydro impurity, Styrene impurity standard into 
separate 20 mL volumetric flasks. Added 5 mL of 
diluent sonicate to dissolve and dilute up to the mark 
with diluent to produce 250 ppm of each i.e solution 
A3, solution B3, solution C3, & solution D3 
respectively. Pipetted  out 0.1 mL each of Impurity 
stock solution in 25 mL volumetric flask and diluted 
upto the mark with diluent (1 ppm of each impurity). 
Unspiked test preparation:  
 As specified under test preparation for 
5mg Chewable tablet. 
Level I – LOQ level:    
Transferred  10 intact tablets into 250 mL 
volumetric flask. Added about 125 mL of diluent and 
volume of solution A3, solution B3, solution C3, and 
solution D3 so that the concentration of impurity 
should be of LOQ level after final dilution of Test. 
Sonicated for 15 minutes with intermittent shaking. 
Diluted upto the mark with diluent and filter through 
0.45µ membrane filter. 
Level II – 50% level:    
Transfered 10 intact tablets into 250 mL 
volumetric flask. Added about 125 mL of diluent and 
0.5 mL each of solution A3, solution B3, solution C3, 
and solution D3 in the flask. Sonicated for 15 minutes 
with intermittent shaking. Diluted upto the mark with 
diluent and filter through 0.45µ membrane filter. 
Level III – 100% level:   
Transfered 10 intact tablets into 250 mL 
volumetric flask. Added about 125 mL of diluent and 
1.0 mL each of solution A3, solution B3, solution C3, 
and solution D3 in the flask. Sonicated for 15 minutes 
with intermittent shaking. Diluted upto the mark with 
diluent and filter through 0.45µ membrane filter. 
 
Level IV – 200% level:   
Transfered 10 intact tablets into 250 mL 
volumetric flask. Added about 125 mL of diluent and 
02. mL each of solution A3, solution B3, solution C3, 
and solution D3 in the flask. Sonicated for 15 minutes 
with intermittent shaking. Diluted upto the mark with 
diluent and filter through 0.45µ membrane filter. 
Each level prepared in triplicate. Injected  Impurity 
standard preparation in six replicates, unspiked test 
preparation in duplicate and each preparation in 
single. Calculated the average area of respective 
impurity in unspiked test preparation and subtract 
from the spiked Test and then calculated the recovery. 
The result was shown in the Table 2, 3 & 4. 
Calculation: 
                                               WS x DV x PI x 1000 
  ppm added  (Actual)   =    ------------------------------- 
                                                         20 x 100 
         
                                      AT x WI x 0.1 x 250 x PI x 1000 
 ppm recovered    =    --------------------------------------------- 
                                           AS x 20 x 25 x 100  
 
                                             ppm recovered x 100 
        % recovery       =       --------------------------------- 
                                               ppm added (actual) 
Where, 
 AT = Corrected peak response of individual impurity from 
test preparation. 
 AS = Mean peak response of individual impurity from 
Impurity standard preparation. 
 WS   = Wt. of individual impurity std. taken in mg for 
impurity Standard stock    preparation 
 DV = volume of Impurity Standard stock preparation 
spiked in mL 
  WI   = Wt. of individual impurity standard taken in mg for 
Impurity standard preparation 
   PI = Potency of the individual impurity standard in % on 
as is basis 
B. Accuracy (Recovery) for Unknown impurities: 
Performed accuracy at 4 levels, viz. LOQ, 50%, 
100% and 200% of specification concentration. 
Spiked Montelukast sodium in the Placebo and 
compared with the Montelukast sodium standard. 
Calculated % recovery of Montelukast.  
Level I – LOQ level:   
Transferred 10 intact placebo tablets into 
250 mL volumetric flask. Added about 125 mL of 
diluent & volume of Montelukast sodium stock 
preparation was added so that the concentration of 
Montelukast sodium should be of LOQ level after 
final dilution of Test. Sonicated for 15 minutes with 
intermittent shaking. Maintained the water of 
sonicator at room temperature within sonication. 
Diluted upto the mark with diluent and filter through 
0.45µ membrane filter. 
Level II – 50% level:  
Transfered 10 intact placebo tablets into 250 
mL volumetric flask. Added about 125 mL of diluent 
and 0.5 mL Montelukast sodium stock preparation in 
the flask. Sonicated for 15 minutes with intermittent 
shaking. Maintained the water of sonicator at room 
temperature within sonication. Diluted upto the mark 
with diluent and filter through 0.45µ membrane filter. 
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Level III – 100% level:  
Transfered 10 intact placebo tablets into 250 
mL volumetric flask. Added about 125 mL of diluent 
and 1.0 mL Montelukast sodium stock preparation in 
the flask. Sonicated  for 15 minutes with intermittent 
shaking. Maintained the water of sonicator at room 
temperature within sonication. Diluted upto the mark 
with diluent and filter through 0.45µ membrane filter. 
Level IV – 200% level:  
Transfered 10 intact placebo tablets into 250 
mL volumetric flask. Added about 125 mL of diluent 
and 2.0 mL Montelukast sodium stock preparation in 
the flask. Sonicated  for 15 minutes with intermittent 
shaking. Maintained the water of sonicator at room 
temperature within sonication. Diluted upto the mark 
with diluent and filter through 0.45µ membrane filter. 
The result was shown in the Table 5. 
1. Precision: 
The precision of an analytical method is the 
closeness of agreement (degree of scatter) between 
series of measurements obtained from multiple 
samplings of the same homogeneous Test under the 
prescribed conditions.  
A. System Precision: 
Injected Blank preparation, Resolution 
preparation in single and standard preparation in six 
replicate and calculated the % RSD for peak area. 
B. Method Precision (Repeatability): 
Repeatability expresses the precision under 
the same operating conditions over a short interval of 
time. Method Precision were established  by carrying 
out related substances test on six Test preparations as 
described in above preparation. Individual known 
impurity value, individual unknown impurity value 
and total impurities were calculated. 
C. Intermediate Precision (Ruggedness): 
Intermediate precision expresses within-
laboratory variation on a different day, by a different 
analyst, using different instrument, different Column 
and using same lot of test as specified under 
repeatability. Calculated individual known impurity 
value, individual unknown impurity value and total 
impurities. The result was shown in the Table 6. 
2. Robustness: 
The robustness of an analytical procedure is 
a measure of its capacity to remain unaffected by 
small, but deliberate variations in method parameters 
and provides indications of its reliability during 
normal usage. 
Following parameter were changed one by one and 
observe their effect on % of impurity. 
i)  Change in Column temperature by ± 2°C (i.e.23°C 
and 27°C) 
ii) Change in the wavelength by + 2 nm (i.e. 223 nm 
and 227 nm) 
iii) Change the pH of Buffer used in the mobile phase 
by ± 0.05 (i.e 4.55 and 4.65) The procedure followed 
for method precision were repeated  by using above 
changes in method one by one except the three Tests 
to be taken instead of six. Also individual known 
impurities, individual unknown and total impurities 
were calculated. The result was shown in the Table 7, 
8, & 9. 
3. Solution Stability: 
Standard preparation and Test preparation 
were prepared as described in the above preparation. 
Standard preparation and Test preparation were 
injected at initial and keep them in auto sampler of 
HPLC at 5°C. Standard preparation and Test 
preparation were Inject at different time interval viz, 
Initial, After 2 Hours and after 4 Hours, also injecting 
the fresh Standard preparation at each time interval 
where ever possible. Calculated the % impurity at 
every time interval. 
4. Filter Paper Interference: 
Filter paper interference was  checked by 
filtering the Standard preparation by selected filter 
paper. Filtered about 10 mL of the Standard 
preparation with 0.45µ nylon membrane filter paper. 
The filtrate was injected along with Unfiltered 
Standard preparation and % variation of filtered 
Standard preparation with Unfiltered Standard 
preparation was calculated. 
 
3. Results and Disscussion                                            
3.1 Optimization of Chromatographic Condition 
for Estimation of Drug 
Instrument : HPLC with gradient pump 
and DAD Detector 
Column : BDS Hypersil C18, 250 mm x 
4.6mm, 5  or equivalent 
Mobile phase : Buffer : Acetonitrile ( 30:70) 
Wavelength : 225 nm 
Flow rate : Gradient programming 
Injection volume : 20 L 
Column 
temperature 
: 25°C 
Auto sampler  
temperature    
: 5°C 
Run time : 45 minutes 
Retention time : about 15 minutes for 
Montelukast  
The result was shown in the Fig 10. 
 The observations and result obtained for 
each parameter including Specificity, Limit Of 
Quantitation, Limit of Detection, Linearity, Accuracy 
(Recovery), Method Precision (Repeatability), 
Intermediate precision (Ruggedness) Robustness, 
Solution Stability and System Suitability. % recovery 
of Montelukast containing unknown impurity was 
found to be 103.6 with % RSD 2.17. Specificity of the 
method was demonstrated by analyzing Blank 
preparation, Placebo preparation, diluted standard 
preparation, Individual Known Impurity preparation, 
Test preparation and Test spiked preparation did not 
show any interference at the Retention time of 
Montelukast Sodium. The robustness of the method 
was evaluated by altering the variables such as 
different Column oven Temperature (23° C and 
27°C), different Wavelength (223 nm and 227 nm) 
and different pH of Buffer (4.55 and 4.65). The data 
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obtained from individual condition shows that the method is robust including repeatability
                                Fig 6 :  λmax spectra of Montelukast 
 
Fig 7 : Chromatogram of Montelukast resolution mixture 
 
Fig 8 : Chromatogram for Diluent 
 
Fig 9: Chromatogram for Placebo 
 
Fig 10: Chromatogram for Montelukast Sample 
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Fig 11 : Chromatogram for Sulphoxide impurity 
 
Fig 12: Chromatogram for Hydroxy impurity 
 
Fig 13: Chromatogram for Dihydro impurity 
 
Fig 14 : Chromatograms of Styrene impurity 
 
Fig 15: Chromatogram for Montelukast 
 
Table 1: Response Factor 
Component Name Relative Retention Time Response Factor 
Sulphoxide impurity 0.37 1.05 
Hydroxy impurity 0.55 0.86 
Dihydro impurity 0.77 0.73 
Montelukast  1.00 1.00 
Styrene impurity 2.02 1.89 
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Table 2: Accuracy (Recovery) for Known impurities: 
Name of Compound Resolution 
Sulphoxide impurity -- 
Hydroxy impurity 11.25 
Dihydro impurity 6.44 
Montelukast Sodium 6.22 
Styrene impurity 23.87 
Table 3 : Styrene impurity standard  
Injection No. Area Asymmetry Theoretical Plates 
1 32242 1.23 23497 
2 32035 1.22 23400 
3 32297 1.14 23454 
4 31444 1.12 23914 
5 31575 1.13 23876 
6 31444 1.19 23486 
Mean 31840 1.17 23605 
Std. Dev. 398.1 --- -- 
% RSD 1.25 --- --- 
Table 4 :  Recovery for Styrene impurity 
Accuracy 
Level 
Sample 
No. 
Actual Amount 
added in mg 
Recovered 
Amount in mg 
% 
Recovery 
Mean % 
Recovery 
Std. 
Dev. 
% 
RSD 
LOQ Level 
1 63.113 57.325 90.8 
96.5 4.91 5.09 2 63.113 62.611 99.2 
3 63.113 62.743 99.4 
Level I     
(50%) 
1 210.375 198.049 94.1 
94.4 0.42 0.44 2 210.375 199.727 94.9 
3 210.375 198.326 94.3 
Level II 
(100%) 
1 420.750 400.802 95.3 
95.2 0.75 0.79 2 420.750 403.326 95.9 
3 420.750 397.129 94.4 
Level III 
(200%) 
1 841.500 799.794 95.0 
95.5 0.55 0.58 2 841.500 808.595 96.1 
3 841.500 803.706 95.5 
   
Overall Mean 
Recovery 
95.4    
   Std. Dev. 2.27    
   % RSD 2.38  
 
 
 
  
Table 5: Accuracy (Recovery) For Unknown Impurity 
Name of 
Impurity 
mean % Recovery Overall Mean 
% Recovery 
STD DEV. %RSD 
Level I 
LOQ 
Level II 
50% 
Level III 
100% 
Level  IV 
150% 
Sulphoxide  
impurity 
104.7 102.6 107.8 98.5 103.4 4.14 4.00 
Hydroxide  
impurity 
104.3 106.4 109.3 102.3 105.6 2.94 2.78 
Dihydro 
impurity 
99.8 102.6 103.9 104.5 102.7 2.62 2.55 
Styrene 
impurity 
104.8 102.7 108.4 103.0 104.7 2.53 2.42 
Montelukast 104.5 103.7 101.8 104.2 103.6 2.25 2.17 
Table 6: Precission 
Type  Mean Area mVS STD DEV. % RSD 
System Precission for Montelukast std 56472 362.99 0.64 
Method Precission for montelukast std (Repeatability) 56472 362.99 0.64 
Intermediate Precission(Ruggedness) 58516 631..56 1.08 
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Table 7: Robustness 
Type 
Resolution of impurities 
Sulphoxide Hydroxy Dihydro Montelukast Styrene 
Change in column oven temperature:23
0
c --- 13.41 8.11 7.34 25.51 
Change in column oven temperature:27
0
c --- 13.23 7.78 7.06 26.28 
Change in wavelength:223 nm --- 13.57 7.42 6.95 26.07 
Change in wavelength:227 nm --- 13.80 7.56 7.09 26.01 
Change in buffer Ph 4.55 --- 13.78 7.64 7.14 26.02 
Change in buffer Ph 4.65 --- 14.37 6.83 6.85 26.04 
Table 8: Robustness For Montelukast Sodium Standard  
Type Mean area Std dev. %RSD 
Change in column oven temperature:230c 58887 309.65 0.53 
Change in column oven temperature:270c 59271 693.26 1.17 
Change in wavelength:223 nm 61164 389.37 0.64 
Change in wavelength:227 nm 56069 134.51 0.24 
Change in buffer pH 4.55 62099 246.05 0.04 
Change in buffer pH 4.65 61535 407.02 0.66 
Table 9: Robustness For % of Impurities 
Type 
Mean %  of impurities test preparation (1,2 and 3) 
% total 
impurities 
Sulphoxide 
impurity 
Hydroxy 
impurity 
Dihydro 
impurity 
Styrene 
impurity 
Individual % 
Unknown 
impurities 
Change in column 
oven temperature: 230c 
0.166 NA NA 
Below 
quantitation limit 
0.986 0.275 
Change in column 
oven temperature: 270c 0.164 
Below 
detection 
limit 
Below 
quantitation 
limit 
Below 
quantitation limit 
0.093 0.280 
Change in 
wavelength:223 nm 
0.171 NA 0.021 
Below 
quantitation limit 
0.084 0.276 
Change in wavelength: 
227 nm 0.167 
Below 
detection 
limit 
NA 
Below 
quantitation limit 
0.086 0.280 
Change in buffer Ph 
4.55 
0.164 NA NA 
Below 
quantitation limit 
0.082 0.276 
Change in buffer Ph 
4.65 
0.163 NA NA 
Below 
quantitation limit 
0.085 0.277 
 
4. Conclusion 
Quantitative determination of the drugs by 
HPLC is very accurate & simple method as compare 
to the other analytical method.  The method gave 
good resolution in Related substances separation 
substances of Montelukast from Montelukast Sodium 
in chewable tablet dosage form. The method has been 
shown to be specific for Montelukast Sodium and 
founded to be linear, precise and accurate across a 
suitable analytical range. Solutions have been shown 
to be stable for at least 24 hours on ambient storage 
condition. The method has been shown to be robust 
towards deliberate minor changes in the method 
parameters. 
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